Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2023 | Highlights from the World Stroke Congress 2023

Michael D. Hill, MD, University of Calgary, Alberta, Canada, discusses key findings presented at the World Stroke Congress (WSC) 2023 in Toronto, Canada. The TENSION trial (NCT03094715) confirmed the safety and efficacy of endovascular thrombectomy (EVT) in patients with extended ischemic stroke lesions (ASPECTS 3-5) and patients presenting in a late time window (up to 12 hours), selected based on standard of care stroke imaging (non-contrast CT/MRI). The results from ATTEST2 (NCT02814409) were also presented, which investigated the use of alteplase versus tenecteplase for intravenous thrombolysis in early acute ischemic stroke. Tenecteplase was found to be non-inferior, which has influenced the switch from alteplase to tenecteplase in stroke treatment. The ANNEXA-I trial (NCT03661528) gave promising results for the use of andexanet alfa in the treatment of patients with intracranial hemorrhage related to factor Xa inhibitor administration. These findings highlight the key advancements in stroke research and offer promising new avenues for enhancing the treatment of stroke patients. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.